肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访

2019-09-24 欧洲肿瘤内科学会 Ann Oncol. 2019 Sep 24.

甲状腺癌

2019年9月，欧洲肿瘤内科学会(ESMO)发布了甲状腺癌的诊断，治疗和随访指南，文章主要目的是为临床医生提供关于特定问题的最佳证据和实用建议。内容涉及甲状腺癌的诊断，治疗以及随访。

中文标题：

2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访

英文标题：

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

发布机构：

欧洲肿瘤内科学会

发布日期：

2019-09-24

简要介绍：

2019年9月，欧洲肿瘤内科学会(ESMO)发布了甲状腺癌的诊断，治疗和随访指南，文章主要目的是为临床医生提供关于特定问题的最佳证据和实用建议。内容涉及甲状腺癌的诊断，治疗以及随访。

 

拓展指南：与甲状腺癌相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访)] GetToolGuiderByIdResponse(projectId=1, id=d13ad1c001e9935a, title=2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访, enTitle=Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., guiderFrom=Ann Oncol. 2019 Sep 24., authorId=null, author=, summary=2019年9月，欧洲肿瘤内科学会(ESMO)发布了甲状腺癌的诊断，治疗和随访指南，文章主要目的是为临床医生提供关于特定问题的最佳证据和实用建议。内容涉及甲状腺癌的诊断，治疗以及随访。 , cover=, journalId=null, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Tue Sep 24 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>2019年9月，欧洲肿瘤内科学会(ESMO)发布了甲状腺癌的诊断，治疗和随访指南，文章主要目的是为临床医生提供关于特定问题的最佳证据和实用建议。内容涉及甲状腺癌的诊断，治疗以及随访。 </P> <P> </P>拓展指南：<strong>与<font color=red>甲状腺癌</font>相关指南：</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=96b171c001e976ed" title="NCCN临床实践指南：甲状腺癌（2019.V2）" target=_blank>NCCN临床实践指南：甲状腺癌（2019.V2）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=53e351c001e683f2" title="碘难治性分化型甲状腺癌的诊治管理共识（2019年版）" target=_blank>碘难治性分化型甲状腺癌的诊治管理共识（2019年版）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=2c1341c001e3507e" title="2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）" target=_blank>2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=c2a5e1c001e302ab" title="NCCN临床实践指南：甲状腺癌（2019.V1）" target=_blank>NCCN临床实践指南：甲状腺癌（2019.V1）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=6c7021c0016826c3" title="NCCN临床实践指南：甲状腺癌（2018.V3）" target=_blank>NCCN临床实践指南：甲状腺癌（2018.V3）</a></li> 更多信息请点击：<a href="https://www.medsci.cn/guideline/list.do?q=%E7%94%B2%E7%8A%B6%E8%85%BA%E7%99%8C" target=_blank>有关甲状腺癌更多指南</a></ul>, tagList=[TagDto(tagId=865, tagName=甲状腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=23, categoryName=普通外科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8586, appHits=781, showAppHits=34, pcHits=4116, showPcHits=5369, likes=64, shares=17, comments=5, approvalStatus=1, publishedTime=Mon Sep 30 13:20:04 CST 2019, publishedTimeString=2019-09-24, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Sep 30 13:20:04 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 19:26:06 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访)])
2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1005474, encodeId=afd610054e4a2, content=好好哈, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00402245638, createdName=12153915m32(暂无昵称), createdTime=Thu Aug 05 22:30:53 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001395, encodeId=e74b10013950f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5553665, createdName=ms5000001563580929, createdTime=Wed Jul 21 14:56:01 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975926, encodeId=9dbd9e592649, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51705231149, createdName=1479ea96m27暂无昵称, createdTime=Tue Jun 22 21:17:07 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900365, encodeId=4f79900365bd, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8be1694397, createdName=1de66f7dm95(暂无匿称), createdTime=Thu Nov 19 08:29:53 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897642, encodeId=98e889e642c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/E84EE939EC9678CDD73767ABCDC8288C/100, createdBy=cc522467391, createdName=凉纪之, createdTime=Sat Nov 07 23:38:11 CST 2020, time=2020-11-07, status=1, ipAttribution=)]
    2021-08-05 12153915m32(暂无昵称)

    好好哈

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1005474, encodeId=afd610054e4a2, content=好好哈, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00402245638, createdName=12153915m32(暂无昵称), createdTime=Thu Aug 05 22:30:53 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001395, encodeId=e74b10013950f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5553665, createdName=ms5000001563580929, createdTime=Wed Jul 21 14:56:01 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975926, encodeId=9dbd9e592649, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51705231149, createdName=1479ea96m27暂无昵称, createdTime=Tue Jun 22 21:17:07 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900365, encodeId=4f79900365bd, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8be1694397, createdName=1de66f7dm95(暂无匿称), createdTime=Thu Nov 19 08:29:53 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897642, encodeId=98e889e642c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/E84EE939EC9678CDD73767ABCDC8288C/100, createdBy=cc522467391, createdName=凉纪之, createdTime=Sat Nov 07 23:38:11 CST 2020, time=2020-11-07, status=1, ipAttribution=)]
    2021-07-21 ms5000001563580929

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1005474, encodeId=afd610054e4a2, content=好好哈, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00402245638, createdName=12153915m32(暂无昵称), createdTime=Thu Aug 05 22:30:53 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001395, encodeId=e74b10013950f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5553665, createdName=ms5000001563580929, createdTime=Wed Jul 21 14:56:01 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975926, encodeId=9dbd9e592649, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51705231149, createdName=1479ea96m27暂无昵称, createdTime=Tue Jun 22 21:17:07 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900365, encodeId=4f79900365bd, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8be1694397, createdName=1de66f7dm95(暂无匿称), createdTime=Thu Nov 19 08:29:53 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897642, encodeId=98e889e642c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/E84EE939EC9678CDD73767ABCDC8288C/100, createdBy=cc522467391, createdName=凉纪之, createdTime=Sat Nov 07 23:38:11 CST 2020, time=2020-11-07, status=1, ipAttribution=)]
    2021-06-22 1479ea96m27暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1005474, encodeId=afd610054e4a2, content=好好哈, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00402245638, createdName=12153915m32(暂无昵称), createdTime=Thu Aug 05 22:30:53 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001395, encodeId=e74b10013950f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5553665, createdName=ms5000001563580929, createdTime=Wed Jul 21 14:56:01 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975926, encodeId=9dbd9e592649, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51705231149, createdName=1479ea96m27暂无昵称, createdTime=Tue Jun 22 21:17:07 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900365, encodeId=4f79900365bd, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8be1694397, createdName=1de66f7dm95(暂无匿称), createdTime=Thu Nov 19 08:29:53 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897642, encodeId=98e889e642c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/E84EE939EC9678CDD73767ABCDC8288C/100, createdBy=cc522467391, createdName=凉纪之, createdTime=Sat Nov 07 23:38:11 CST 2020, time=2020-11-07, status=1, ipAttribution=)]
    2020-11-19 1de66f7dm95(暂无匿称)

    6666

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1005474, encodeId=afd610054e4a2, content=好好哈, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00402245638, createdName=12153915m32(暂无昵称), createdTime=Thu Aug 05 22:30:53 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001395, encodeId=e74b10013950f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5553665, createdName=ms5000001563580929, createdTime=Wed Jul 21 14:56:01 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975926, encodeId=9dbd9e592649, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51705231149, createdName=1479ea96m27暂无昵称, createdTime=Tue Jun 22 21:17:07 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900365, encodeId=4f79900365bd, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8be1694397, createdName=1de66f7dm95(暂无匿称), createdTime=Thu Nov 19 08:29:53 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897642, encodeId=98e889e642c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/E84EE939EC9678CDD73767ABCDC8288C/100, createdBy=cc522467391, createdName=凉纪之, createdTime=Sat Nov 07 23:38:11 CST 2020, time=2020-11-07, status=1, ipAttribution=)]
    2020-11-07 凉纪之

    学习

    0

相关指南

2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）

中国临床肿瘤学会(CSCO,Chinese Society of Clinical Oncology) · 2019-02-20

甲状腺癌诊疗规范（2018年版）

中华人民共和国国家卫生健康委员会 · 2018-12-13

2018 波兰国家指南：甲状腺癌的诊断和治疗（更新版）

国外肿瘤科相关专家小组（统称） · 2018-08-20

甲状腺癌血清标志物临床应用专家共识（2017 版）

中国抗癌协会甲状腺癌专业委员会(CATO) · 2018-01-30

美国甲状腺学会《儿童甲状腺结节与分化型甲状腺癌诊治指南》解读

暂未更新 · 2017-08-30